Michael E. Jung is Awarded the 2022 IUPAC-Richter Prize

doi:10.1515/ci-2022-0206

Article Publicly Available

Michael E. Jung is Awarded the 2022 IUPAC-Richter Prize

Published/Copyright: April 14, 2022

Published by

Become an author with De Gruyter Brill

Author Information

From the journal Chemistry International Volume 44 Issue 2

Abstract

Michael E. Jung, of the Department of Chemistry and Biochemistry at UCLA, has been awarded the 2022 IUPAC-Richter Prize in recognition of his research, which has afforded new drugs for the treatment of advanced prostate cancer. The acceptance lecture will be held in New York, NY, USA (26-29 June 2022) at the 37th ACS National Medicinal Chemistry Symposium and Jung will present a second lecture at the XXVII EFMC International Symposium on Medicinal Chemistry in Nice, France (4-8 Sept 2022).

Michael E. Jung, recipient of the 2022 IUPAC-Richter Prize, in recognition of his research which has afforded new drugs for the treatment of advanced prostate cancer.

In 1978, Michael Jung began a career as a synthetic organic chemistry consultant for many industrial firms, mostly pharmaceutical or agricultural firms, in both big pharma and biotechs. At one point, he consulted at the same time for more than 25 industrial companies. From the start at UCLA, he was involved in the total synthesis of natural products and the development of new synthetic methods. He published extensively in those two areas and was honored with several awards, e.g., the Arthur C. Cope Scholar Award in 1995. In 2003, and after a career as a synthetic organic chemist, he made a career shift and decided to become a medicinal chemist in order to try to get a drug for some human disease out of the lab. He had never studied or practiced medicinal chemistry but he figured he had learned something consulting all those years in pharma. He quickly hired a postdoc and let everyone in biology and the medical school at UCLA know that they were ready to help, if chemistry could somehow move their project forward. In close collaboration with Charles Sawyers, Jung designed and synthesized two different compounds for the treatment of castration-resistant prostate cancer (CRPC). The first compound, enzalutamide (Xtandi), was approved in August 2012 for the treatment of both metastatic post-chemotherapy and pre-chemotherapy CRPC. His second drug, apalutamide (Erleada), was approved in February 2018 for pre-metastatic CRPC. Just recently, it was reported to also work for metastatic castration-sensitive prostate cancer.

In honor of his drug discovery work which has led to two FDA approvals, he was named the University of California Presidential Chair in Medicinal Chemistry in 2018. In his career, he has supervised 94 PhD students, 9 MS students, 47 undergraduates, 134 postdoctoral associates, and 21 research associates. Over the years, he has co-founded 14 biotechs, 10 of which are still operating.

This year marks the ninth occasion of the IUPAC-Richter Prize, which was established in 2005 by the IUPAC and Richter PLC. Awarded biannually, the awardee is announced following nominations and the decision of an independent international selection committee. The awardee is expected to give two lectures, one in Europe and one in the United States, at international symposia on medicinal chemistry. The lecture in which the prize is awarded occurs alternatively in Europe and in the United States. The awardee receives an award of $ 10,000, which is sponsored by Richter PLC, and a plaque, which is presented by IUPAC.

The previous awardees are: 2006, Malcolm FG Stevens (UK); 2008, Jan Heeres (Belgium); 2010, Arun Ghosh (USA); 2012, Stephen Hanessian (Canada); 2014, Helmut Buschmann (Germany); 2016, Michael Sofia (USA); 2018, Peter Grootenhuis (USA); and 2020, John Macor (USA).

https://iupac.org/what-we-do/awards/iupac-richter-prize-medicinal-chemistry/

Online erschienen: 2022-04-14

Erschienen im Druck: 2022-04-01

©2022 IUPAC & De Gruyter. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. For more information, please visit: http://creativecommons.org/licenses/by-nc-nd/4.0/

Articles in the same Issue

https://doi.org/10.1515/ci-2022-0206